Core Viewpoint - BaiO Pharmaceutical-B (02315) experienced a significant increase of nearly 20%, closing at 34.3 HKD, following its inclusion in the Hong Kong Stock Connect list effective December 24, 2025 [1] Company Summary - BaiO Pharmaceutical is recognized as a leading preclinical CRO and life sciences company in China, possessing a globally advanced gene editing technology platform [1] - The company has a rich resource of model mice and is actively developing its antibody development business through the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - There is strong growth potential for its overseas business, indicating a promising outlook for future expansion [1]

Core Viewpoint - BaiO Saite-B (02315) experienced a significant increase of nearly 20% in early trading, with a current price of 34.3 HKD and a trading volume of 22.7351 million HKD, following the announcement of its inclusion in the Hong Kong Stock Connect program effective December 24, 2025 [1] Group 1 - The Shanghai and Shenzhen Stock Exchanges announced the adjustment of the Hong Kong Stock Connect securities list, which includes BaiO Saite-B after the price stabilization period in the Hong Kong market ended and the corresponding A-share listing has been active for 10 trading days [1] - BaiO Saite is recognized as a leading preclinical CRO and life technology company in China, possessing a globally advanced gene editing technology platform and a rich resource of model mice [1] - The company is actively developing its antibody development business through the "Thousand Mice and Ten Thousand Antibodies" initiative, indicating strong growth potential in its overseas business [1]

Group 1 - The core viewpoint of the article highlights a significant increase in the stock price of Baiaosaitu-B (02315), which surged nearly 20% in early trading, reaching HKD 34.3 with a trading volume of HKD 22.7351 million [1] - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that Baiaosaitu-B will be added to the Hong Kong Stock Connect eligible securities list effective December 24, 2025, following the end of its price stabilization period in the Hong Kong market and after being listed for 10 trading days in A-shares [1] - Guotai Junan Securities previously noted that Baiaosaitu is a leading preclinical CRO and life technology company in China, possessing a globally advanced gene editing technology platform and abundant resources of model mice, significantly developing its antibody development business through the "Thousand Mice and Ten Thousand Antibodies" initiative, with strong growth potential in overseas markets [1]